Baudax Bio, Inc. (BXRXQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Geraldine A. Henwood Ph.D. | President, CEO & Director | 633.25k | -- | 1952 |
| Mike Choi | Vice President of Financial Planning & Analysis | -- | -- | -- |
| Ms. Natalie McAndrew | Consultant & Principle Accounting Officer | -- | -- | 1972 |
| Dr. Chan Kim Yong Ph.D. | Chief Scientific Officer & Director | -- | -- | 1974 |
Baudax Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Corporate Governance
Upcoming Events
February 12, 2025 at 9:00 PM UTC - February 15, 2025 at 9:00 PM UTC
Baudax Bio, Inc. Earnings Date
Recent Events
September 21, 2023 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission